MBIO — MindBio Therapeutics Income Statement
0.000.00%
Last trade - 00:00- CA$3.53m
- CA$7.86m
Annual income statement for MindBio Therapeutics, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Depreciation and Amortization | ||||
| Unusual Expense / Income | ||||
| Total Operating Expenses | 0.477 | 7.51 | 3.72 | 0.725 |
| Operating Profit | -0.477 | -7.51 | -3.72 | -0.725 |
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | -0.477 | -7.51 | -4.29 | -0.416 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | -0.477 | -7.51 | -4.29 | -0.416 |
| Minority Interest | ||||
| Net Income Before Extraordinary Items | ||||
| Net Income | -0.477 | -7.51 | -4.28 | -0.416 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Dilution Adjustment | ||||
| Diluted Net Income | -0.477 | -7.51 | -4.28 | -0.416 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -0.004 | -0.044 | -0.039 | -0.006 |
| Dividends per Share |